Multiple sclerosis (MS) is an increasingly complex disease in terms of its pathogen esis, comorbidities, prognosis and treatment, and successful patient management requires knowledge of this complexity. 2015 saw advances in our understanding of the mech anisms of the disease, ways in which to for mulate patient prognoses, how best to escalate treatment, and the role of comorbidities. All of these aspects need to be incorporated into an effective patient management plan (FIG. 1) .
The mechanisms that underlie the patho genesis of MS are yet to be fully elucidated, but they are known to include a cascade of events that induce physical and cognitive deficits. A reduction in neuronal integrity and function that affects the grey matter compartment is thought to be the key pathological process that leads to cognitive impairment in MS.
Findings of a study published by Freeman et al. 1 in 2015 suggest that synaptic and/or dendritic damage occurs prior to quantifi able grey matter volume loss, and might reflect neuronal and axonal loss that contributes to clinical deficits. In this study, Freeman A study published by Tintore et al. 4 in 2015 illustrates the importance of this stratifica tion step. This study included a singlecentre cohort of 1,015 patients with CIS who were clinically and radiologically followed up for a mean of 6.8 years 4 . The results showed that ≥10 brain lesions visible with MRI at the onset of CIS was highly predictive (classified in the study as a "high impact" prognostic factor) of development of MS and disability. The pres ence of oligoclonal bands in the cerebrospinal fluid was also predictive, but to a lesser extent (classified as a "mediumimpact" prognostic factor). Presentation of CIS with optic neuritis and the use of a diseasemodifying treatment had a (probably marginal) protective effect against the development of MS and disability. insular cortices and the left frontal cortex) and subcortical regions (the thalamus, hippocam pus and amygdala) in patients with MS than in healthy controls. Greater amounts of neu ronal damage were seen in patients with sec ondary progressive MS than in patients with relapsing-remitting MS (RRMS), but the most striking result was that [ Managing the complexity of multiple sclerosis
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The application of imaging biomarkers has provided new insights into the mechanisms of damage in multiple sclerosis (MS) and the risk of MS development and progression. The goal of eliminating all disease activity requires a timely escalation of treatment. This increasing complexity is compounded by the need to treat comorbidities.
Figure 1 | Towards successful management of the complexity of multiple sclerosis (MS).
An understanding of the pathogenic mechanisms, progression, comorbidities and optimal treatment escalation is necessary to formulate a treatment plan for individuals with MS.
Other demographic factors, such as gender and age at onset, were "lowimpact" prognos tic factors. The study had some methodologi cal limitations, such as the number of patients who dropped out during followup (unavoid able in this type of longitudinal study) and the fact that the latest 2010 McDonald diag nostic criteria were not used. Nevertheless, the results provide further clarity about the hetero geneous outcomes of patients with CIS and help to inform their prognosis.
The ability to predict disease course in RRMS is particularly important now that we have a range of new treatments for the disease; although there is now a consensus that early treatment is optimum, the nature and timing of escalation to secondline treatment remains a challenge. The ultimate goal of such esca lation is to increase the chance that patients reach a longterm status of 'no evidence of disease activity (NEDA)' 5 . A central question that surrounds second line treatment is whether natalizumab is more effective than fingolimod once failure of firstline treatment has been established. A headtohead comparison between these two drugs is unlikely to be conducted, but Kalincik et al. 6 in 2015 extracted data from the MSBase registry to compare the out comes of treatment escalation to natalizumab or fingolimod in patients with MS who had experienced disease activity while receiving injectable diseasemodifying treatments. The relapse rate after switching to natali zumab was 50% lower than after switching to fingo limod, with a corresponding increase in the proportion of relapsefree patients on natalizumab. Importantly, however, 6month sustained disability progression rates did not differ between the two treatments. This finding highlights the need to identify new treatments that can slow or stop progression of MS, a major initiative being driven by the Progressive MS Alliance, who, in 2015, published an appraisal of current knowledge in this area and suggested future steps 3 . One other important consideration is that drug efficacy is only one factor that is considered by doctors and patients when discussing treatment escalation; treatment safety and tolerability, together with risk assessment 7 , are additional important elements, particularly from the patient's perspective.
In addition to specific treatment appro aches, a holistic approach to management, including a focus on wellbeing, is paramount, and identifying and managing comorbidities is an important element of this approach. The impact of comorbidities on clinical symptoms and disability progression in MS is becoming clear, and knowledge of how physical and mental comorbidities affect MS will improve management of the complexity of the disease.
In 2015, Marrie et al. 8 addressed the ques tion of whether comorbidities are responsible for the reduced survival associated with MS. They used populationbased administra tive data to study 5,797 people with MS and 28,807 healthy controls who were matched for sex, year of birth and geographical region. Median survival from birth was 75.9 years in the MS population, and 83.4 years in the control population, which corresponded to a twofold unadjusted increase in the hazard of death in the MS population. Comorbidities (depression, diabetes and ischaemic heart dis ease) were associated with increased mortality in MS, but did not confer a greater risk of mor tality in the MS population than in the control population. Mortality from infectious diseases and diseases of the respiratory system was higher in the MS population than in the con trol population. These findings extend the results of previous studies that reported an effect of comorbidity on the diagnosis of and disability in MS 9 , suggesting that treatment and prevention of comorbidities improves sur vival in MS. Future research will fill important gaps in our knowledge about the worldwide epidemiology of comorbidity in MS 10 . These recent advances in MS research and clinical trials will help clinicians to manage the complexity of MS in clinical practice and will inform future research in the field. We antici pate that 2016 will bring major advances in the treatment of progressive MS, which remains a substantial unmet need 3 .
